← boardnext 2028-05-31next 2030-01
CNTX
Context Therapeutics Inc.distress 2/10 · well-funded / low risk$0.62+1%today-82% from 52w high
Lead: Colorectal Cancer · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$55M
Runway
1.7 yrs
Shares 1y
+2%
Price & events
-65.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.1%
1D
+0.8%
1W
-5.0%
1M
-73.3%
3M
-65.8%
6M
-25.3%
1Y
-72.1%
2Y
—
5Y
-87.8%
All
Overview
- Market Cap
- $56.94M
- Volume
- 74.36K
- 52 Week Range
- $0.55 – $3.36
- Total Shares
- 91.88M
- Float Shares
- 42.82M
- Short %
- 4.03%
- % Held by Insiders
- 1.35%
- % Held by Institutions
- 81.37%
- RVOL
- 0.02x
- Beta
- 1.75
Pipeline stages · 2 programs
CTIM-76
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CT-202
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | CT-95 | Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer | — | recruiting |
| 2028-05-31 Estimated 50% readout ~2028-06-30 | Phase 1 | CTIM-76fast track | Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer | — | recruiting |
| 2030-01 Estimated 50% readout ~2030-01-31 | Phase 1 | CT-202 | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | — | not yet recruiting |
Catalyst news & presentations · 4
- second quarter of 2026regulatory submissionFiled (NDA/BLA)CT-202 · Complete regulatory filings to support first-in-human trial initiationSEC 8-K
- middle of 2026readoutPhase 1CT-95 · Initial Phase 1a dataSEC 8-K
- second quarter of 2026readoutPhase 1CTIM-76 · Updated interim Phase 1a data and Phase 1b dose selectionSEC 8-K
- 2026-05-14partnershipCT-202 · Amended license to obtain exclusive, royalty-free, fully paid-up rights to CT-202; pays $4.5M immediately and $2M by Aug 1, 2026.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $5 (+767% upside) · 8 analysts
- 2026-06-16Maxim GroupBuy
- 2026-03-24D. Boral CapitalBuy
- 2026-03-24GuggenheimBuy
- 2026-03-24Piper SandlerOverweight
- 2025-12-22Jones TradingBuy
- 2025-11-06D. Boral CapitalBuy
Competitors — Colorectal Cancer
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- BNTXBioNTech SE$23.1B · D1
- SMMTSummit Therapeutics Inc.$11.6B · D3
- IDYAIDEAYA Biosciences, Inc.$3.0B · D3
- VSTMVerastem, Inc.$515M · D5
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRDFCardiff Oncology, Inc.$59M · D3
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-16Enterprise value to revenue forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
- 2026-07-14Centex Price Today in India | CNTX to INR Live Price & Chart - Binance
- 2026-07-14Context Grants 146,000-Share Option to New Employee - MyChesCo
- 2026-07-14Context Therapeutics Q1 2026 Earnings: EPS Beat by 24.81% Offset by Stock Decline Amid Pre-Revenue Stage - dars.gov.et
- 2026-07-11Price to earnings forward of PT Century Textile Industry Tbk Pfd Series A – IDX:CNTX - TradingView
- 2026-07-11Context Therapeutics (CNTX) Proxy filing Summary - Quartr
- 2026-07-11Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-11Context Therapeutics (CNTX) Proxy filing Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.